JP2016526393A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016526393A5 JP2016526393A5 JP2016525467A JP2016525467A JP2016526393A5 JP 2016526393 A5 JP2016526393 A5 JP 2016526393A5 JP 2016525467 A JP2016525467 A JP 2016525467A JP 2016525467 A JP2016525467 A JP 2016525467A JP 2016526393 A5 JP2016526393 A5 JP 2016526393A5
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- disease
- seq
- amino acid
- kit
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 208000015122 neurodegenerative disease Diseases 0.000 claims description 30
- 238000000034 method Methods 0.000 claims description 28
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 22
- 230000024203 complement activation Effects 0.000 claims description 22
- 201000010099 disease Diseases 0.000 claims description 20
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 20
- 210000000225 synapse Anatomy 0.000 claims description 20
- 208000023275 Autoimmune disease Diseases 0.000 claims description 14
- 239000000427 antigen Substances 0.000 claims description 12
- 108091007433 antigens Proteins 0.000 claims description 12
- 102000036639 antigens Human genes 0.000 claims description 12
- 102000004169 proteins and genes Human genes 0.000 claims description 12
- 108090000623 proteins and genes Proteins 0.000 claims description 12
- 239000012472 biological sample Substances 0.000 claims description 10
- 108010047295 complement receptors Proteins 0.000 claims description 10
- 102000006834 complement receptors Human genes 0.000 claims description 10
- 208000005590 Choroidal Neovascularization Diseases 0.000 claims description 8
- 206010060823 Choroidal neovascularisation Diseases 0.000 claims description 8
- 206010047115 Vasculitis Diseases 0.000 claims description 8
- 206010064930 age-related macular degeneration Diseases 0.000 claims description 8
- 230000004071 biological effect Effects 0.000 claims description 8
- 230000002612 cardiopulmonary effect Effects 0.000 claims description 8
- 201000005667 central retinal vein occlusion Diseases 0.000 claims description 8
- 230000001419 dependent effect Effects 0.000 claims description 8
- 210000004408 hybridoma Anatomy 0.000 claims description 8
- 208000027866 inflammatory disease Diseases 0.000 claims description 8
- 208000028867 ischemia Diseases 0.000 claims description 8
- 208000002780 macular degeneration Diseases 0.000 claims description 8
- 208000030159 metabolic disease Diseases 0.000 claims description 8
- 208000008795 neuromyelitis optica Diseases 0.000 claims description 8
- 208000004644 retinal vein occlusion Diseases 0.000 claims description 8
- 206010039073 rheumatoid arthritis Diseases 0.000 claims description 8
- 230000000946 synaptic effect Effects 0.000 claims description 8
- 230000035699 permeability Effects 0.000 claims description 7
- 230000007470 synaptic degeneration Effects 0.000 claims description 7
- 108010021625 Immunoglobulin Fragments Proteins 0.000 claims description 6
- 102000008394 Immunoglobulin Fragments Human genes 0.000 claims description 6
- 206010057249 Phagocytosis Diseases 0.000 claims description 6
- 210000004027 cell Anatomy 0.000 claims description 6
- 230000008782 phagocytosis Effects 0.000 claims description 6
- 208000009304 Acute Kidney Injury Diseases 0.000 claims description 4
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 claims description 4
- 208000026872 Addison Disease Diseases 0.000 claims description 4
- 208000024827 Alzheimer disease Diseases 0.000 claims description 4
- 208000003343 Antiphospholipid Syndrome Diseases 0.000 claims description 4
- 208000015943 Coeliac disease Diseases 0.000 claims description 4
- 206010055665 Corneal neovascularisation Diseases 0.000 claims description 4
- 208000011231 Crohn disease Diseases 0.000 claims description 4
- 206010012688 Diabetic retinal oedema Diseases 0.000 claims description 4
- 206010012689 Diabetic retinopathy Diseases 0.000 claims description 4
- 201000010374 Down Syndrome Diseases 0.000 claims description 4
- 206010048554 Endothelial dysfunction Diseases 0.000 claims description 4
- 208000007465 Giant cell arteritis Diseases 0.000 claims description 4
- 208000010412 Glaucoma Diseases 0.000 claims description 4
- 206010018364 Glomerulonephritis Diseases 0.000 claims description 4
- 206010072579 Granulomatosis with polyangiitis Diseases 0.000 claims description 4
- 208000030836 Hashimoto thyroiditis Diseases 0.000 claims description 4
- 208000035186 Hemolytic Autoimmune Anemia Diseases 0.000 claims description 4
- 201000002563 Histoplasmosis Diseases 0.000 claims description 4
- 208000023105 Huntington disease Diseases 0.000 claims description 4
- 208000010159 IgA glomerulonephritis Diseases 0.000 claims description 4
- 206010021263 IgA nephropathy Diseases 0.000 claims description 4
- 208000005777 Lupus Nephritis Diseases 0.000 claims description 4
- 208000004451 Membranoproliferative Glomerulonephritis Diseases 0.000 claims description 4
- 208000000112 Myalgia Diseases 0.000 claims description 4
- 206010068871 Myotonic dystrophy Diseases 0.000 claims description 4
- 208000008589 Obesity Diseases 0.000 claims description 4
- 208000018737 Parkinson disease Diseases 0.000 claims description 4
- 201000011152 Pemphigus Diseases 0.000 claims description 4
- 241000721454 Pemphigus Species 0.000 claims description 4
- 208000031845 Pernicious anaemia Diseases 0.000 claims description 4
- 206010035669 Pneumonia aspiration Diseases 0.000 claims description 4
- 208000033626 Renal failure acute Diseases 0.000 claims description 4
- 208000017442 Retinal disease Diseases 0.000 claims description 4
- 206010038923 Retinopathy Diseases 0.000 claims description 4
- 208000025747 Rheumatic disease Diseases 0.000 claims description 4
- 102000004584 Somatomedin Receptors Human genes 0.000 claims description 4
- 108010017622 Somatomedin Receptors Proteins 0.000 claims description 4
- 102000007238 Transferrin Receptors Human genes 0.000 claims description 4
- 108010033576 Transferrin Receptors Proteins 0.000 claims description 4
- 206010044688 Trisomy 21 Diseases 0.000 claims description 4
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 claims description 4
- 206010046851 Uveitis Diseases 0.000 claims description 4
- 206010047642 Vitiligo Diseases 0.000 claims description 4
- 201000011040 acute kidney failure Diseases 0.000 claims description 4
- 208000012998 acute renal failure Diseases 0.000 claims description 4
- 238000011316 allogeneic transplantation Methods 0.000 claims description 4
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 claims description 4
- 238000004458 analytical method Methods 0.000 claims description 4
- 201000009807 aspiration pneumonia Diseases 0.000 claims description 4
- 208000006673 asthma Diseases 0.000 claims description 4
- 201000000448 autoimmune hemolytic anemia Diseases 0.000 claims description 4
- 210000004369 blood Anatomy 0.000 claims description 4
- 239000008280 blood Substances 0.000 claims description 4
- 230000001684 chronic effect Effects 0.000 claims description 4
- 208000025302 chronic primary adrenal insufficiency Diseases 0.000 claims description 4
- 201000000159 corneal neovascularization Diseases 0.000 claims description 4
- 210000004351 coronary vessel Anatomy 0.000 claims description 4
- 208000001309 degenerative myopia Diseases 0.000 claims description 4
- 230000004340 degenerative myopia Effects 0.000 claims description 4
- 201000001981 dermatomyositis Diseases 0.000 claims description 4
- 206010012601 diabetes mellitus Diseases 0.000 claims description 4
- 201000011190 diabetic macular edema Diseases 0.000 claims description 4
- 230000009429 distress Effects 0.000 claims description 4
- 206010014801 endophthalmitis Diseases 0.000 claims description 4
- 230000008694 endothelial dysfunction Effects 0.000 claims description 4
- 239000012634 fragment Substances 0.000 claims description 4
- 210000000274 microglia Anatomy 0.000 claims description 4
- 201000006417 multiple sclerosis Diseases 0.000 claims description 4
- 206010028417 myasthenia gravis Diseases 0.000 claims description 4
- 230000001537 neural effect Effects 0.000 claims description 4
- 235000020824 obesity Nutrition 0.000 claims description 4
- 230000000414 obstructive effect Effects 0.000 claims description 4
- 208000012111 paraneoplastic syndrome Diseases 0.000 claims description 4
- 230000001575 pathological effect Effects 0.000 claims description 4
- 201000001976 pemphigus vulgaris Diseases 0.000 claims description 4
- 238000013138 pruning Methods 0.000 claims description 4
- 230000002685 pulmonary effect Effects 0.000 claims description 4
- 230000010410 reperfusion Effects 0.000 claims description 4
- 210000001210 retinal vessel Anatomy 0.000 claims description 4
- 230000000552 rheumatic effect Effects 0.000 claims description 4
- 238000001356 surgical procedure Methods 0.000 claims description 4
- 208000011580 syndromic disease Diseases 0.000 claims description 4
- 206010043207 temporal arteritis Diseases 0.000 claims description 4
- 208000037816 tissue injury Diseases 0.000 claims description 4
- 208000006542 von Hippel-Lindau disease Diseases 0.000 claims description 4
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 3
- 210000004556 brain Anatomy 0.000 claims description 3
- 150000007523 nucleic acids Chemical group 0.000 claims description 3
- 108091033319 polynucleotide Proteins 0.000 claims description 3
- 102000040430 polynucleotide Human genes 0.000 claims description 3
- 239000002157 polynucleotide Substances 0.000 claims description 3
- 235000002198 Annona diversifolia Nutrition 0.000 claims description 2
- 108010071134 CRM197 (non-toxic variant of diphtheria toxin) Proteins 0.000 claims description 2
- 238000009007 Diagnostic Kit Methods 0.000 claims description 2
- 238000002965 ELISA Methods 0.000 claims description 2
- 238000012413 Fluorescence activated cell sorting analysis Methods 0.000 claims description 2
- 102000003746 Insulin Receptor Human genes 0.000 claims description 2
- 108010001127 Insulin Receptor Proteins 0.000 claims description 2
- 241000282842 Lama glama Species 0.000 claims description 2
- 101710172064 Low-density lipoprotein receptor-related protein Proteins 0.000 claims description 2
- 108010003723 Single-Domain Antibodies Proteins 0.000 claims description 2
- 238000001574 biopsy Methods 0.000 claims description 2
- 230000008499 blood brain barrier function Effects 0.000 claims description 2
- 210000001218 blood-brain barrier Anatomy 0.000 claims description 2
- GBVKRUOMSUTVPW-AHNVSIPUSA-N chembl1089636 Chemical compound N([C@H]([C@@H](OC(=O)CCC(=O)N[C@@H](C(O)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)NCC(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CCCCNC(=O)CCC(=O)O[C@H]([C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)C(=O)O[C@@H]1C(=C2[C@@H](OC(C)=O)C(=O)[C@]3(C)[C@@H](O)C[C@H]4OC[C@]4([C@H]3[C@H](OC(=O)C=3C=CC=CC=3)[C@](C2(C)C)(O)C1)OC(C)=O)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCCNC(=O)CCC(=O)O[C@H]([C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)C(=O)O[C@@H]1C(=C2[C@@H](OC(C)=O)C(=O)[C@]3(C)[C@@H](O)C[C@H]4OC[C@]4([C@H]3[C@H](OC(=O)C=3C=CC=CC=3)[C@](C2(C)C)(O)C1)OC(C)=O)C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(O)=O)C(=O)O[C@@H]1C(=C2[C@@H](OC(C)=O)C(=O)[C@]3(C)[C@@H](O)C[C@H]4OC[C@]4([C@H]3[C@H](OC(=O)C=3C=CC=CC=3)[C@](C2(C)C)(O)C1)OC(C)=O)C)C=1C=CC=CC=1)C(=O)C1=CC=CC=C1 GBVKRUOMSUTVPW-AHNVSIPUSA-N 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 238000003365 immunocytochemistry Methods 0.000 claims description 2
- 238000010820 immunofluorescence microscopy Methods 0.000 claims description 2
- 238000003364 immunohistochemistry Methods 0.000 claims description 2
- 238000001114 immunoprecipitation Methods 0.000 claims description 2
- 108010046239 paclitaxel-Angiopep-2 conjugate Proteins 0.000 claims description 2
- 108010043655 penetratin Proteins 0.000 claims description 2
- MCYTYTUNNNZWOK-LCLOTLQISA-N penetratin Chemical compound C([C@H](NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](N)CCCNC(N)=N)[C@@H](C)CC)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(N)=O)C1=CC=CC=C1 MCYTYTUNNNZWOK-LCLOTLQISA-N 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims description 2
- 108010011110 polyarginine Proteins 0.000 claims description 2
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 2
- 230000026683 transduction Effects 0.000 claims description 2
- 238000010361 transduction Methods 0.000 claims description 2
- 230000032258 transport Effects 0.000 claims description 2
- 102400001369 Heparin-binding EGF-like growth factor Human genes 0.000 claims 1
- 101800001649 Heparin-binding EGF-like growth factor Proteins 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 102000004196 processed proteins & peptides Human genes 0.000 claims 1
- 125000000539 amino acid group Chemical group 0.000 description 70
- 238000010494 dissociation reaction Methods 0.000 description 14
- 230000005593 dissociations Effects 0.000 description 14
- 206010018910 Haemolysis Diseases 0.000 description 10
- 230000008588 hemolysis Effects 0.000 description 10
- 230000004913 activation Effects 0.000 description 6
- 150000001413 amino acids Chemical class 0.000 description 5
- 108010074051 C-Reactive Protein Proteins 0.000 description 4
- 102100032752 C-reactive protein Human genes 0.000 description 4
- 238000002591 computed tomography Methods 0.000 description 4
- 230000003472 neutralizing effect Effects 0.000 description 4
- TZCPCKNHXULUIY-RGULYWFUSA-N 1,2-distearoyl-sn-glycero-3-phosphoserine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OC[C@H](N)C(O)=O)OC(=O)CCCCCCCCCCCCCCCCC TZCPCKNHXULUIY-RGULYWFUSA-N 0.000 description 2
- 102000013455 Amyloid beta-Peptides Human genes 0.000 description 2
- 108010090849 Amyloid beta-Peptides Proteins 0.000 description 2
- 102000004082 Calreticulin Human genes 0.000 description 2
- 108090000549 Calreticulin Proteins 0.000 description 2
- 102100037078 Complement component 1 Q subcomponent-binding protein, mitochondrial Human genes 0.000 description 2
- ZWZWYGMENQVNFU-UHFFFAOYSA-N Glycerophosphorylserin Natural products OC(=O)C(N)COP(O)(=O)OCC(O)CO ZWZWYGMENQVNFU-UHFFFAOYSA-N 0.000 description 2
- 101000740725 Homo sapiens Complement component 1 Q subcomponent-binding protein, mitochondrial Proteins 0.000 description 2
- 230000006052 T cell proliferation Effects 0.000 description 2
- 210000003719 b-lymphocyte Anatomy 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 108010062119 complement 1q receptor Proteins 0.000 description 2
- 230000004540 complement-dependent cytotoxicity Effects 0.000 description 2
- 230000016396 cytokine production Effects 0.000 description 2
- 230000004041 dendritic cell maturation Effects 0.000 description 2
- 230000016784 immunoglobulin production Effects 0.000 description 2
- 230000006724 microglial activation Effects 0.000 description 2
- 210000001640 nerve ending Anatomy 0.000 description 2
- 230000004770 neurodegeneration Effects 0.000 description 2
- 230000037361 pathway Effects 0.000 description 2
- -1 TMEM30 (A) Proteins 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 206010013023 diphtheria Diseases 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 238000002600 positron emission tomography Methods 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 238000002603 single-photon emission computed tomography Methods 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 108700012359 toxins Proteins 0.000 description 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361844369P | 2013-07-09 | 2013-07-09 | |
| US61/844,369 | 2013-07-09 | ||
| US201361871813P | 2013-08-29 | 2013-08-29 | |
| US61/871,813 | 2013-08-29 | ||
| PCT/US2014/046042 WO2015006504A1 (en) | 2013-07-09 | 2014-07-09 | Anti-complement factor c1q antibodies and uses thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018243892A Division JP6653009B2 (ja) | 2013-07-09 | 2018-12-27 | 抗補体因子Ｃ１ｑ抗体及びその使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2016526393A JP2016526393A (ja) | 2016-09-05 |
| JP2016526393A5 true JP2016526393A5 (enExample) | 2017-08-10 |
| JP6462680B2 JP6462680B2 (ja) | 2019-01-30 |
Family
ID=52280583
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016525467A Active JP6462680B2 (ja) | 2013-07-09 | 2014-07-09 | 抗補体因子Ｃ１ｑ抗体及びその使用 |
| JP2018243892A Active JP6653009B2 (ja) | 2013-07-09 | 2018-12-27 | 抗補体因子Ｃ１ｑ抗体及びその使用 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018243892A Active JP6653009B2 (ja) | 2013-07-09 | 2018-12-27 | 抗補体因子Ｃ１ｑ抗体及びその使用 |
Country Status (23)
| Country | Link |
|---|---|
| US (7) | US20160159890A1 (enExample) |
| EP (3) | EP3019523A4 (enExample) |
| JP (2) | JP6462680B2 (enExample) |
| KR (1) | KR102321320B1 (enExample) |
| CN (1) | CN105682740B (enExample) |
| AU (1) | AU2014287221C1 (enExample) |
| BR (1) | BR112016000106B1 (enExample) |
| CA (1) | CA2916521C (enExample) |
| DK (1) | DK3019240T3 (enExample) |
| EA (1) | EA037325B1 (enExample) |
| ES (1) | ES2978917T3 (enExample) |
| FI (1) | FI3019240T3 (enExample) |
| HU (1) | HUE066722T2 (enExample) |
| IL (1) | IL243506B (enExample) |
| MX (2) | MX375500B (enExample) |
| MY (1) | MY175896A (enExample) |
| NZ (1) | NZ715455A (enExample) |
| PL (1) | PL3019240T3 (enExample) |
| PT (1) | PT3019240T (enExample) |
| SG (3) | SG11201510316UA (enExample) |
| SI (1) | SI3019240T1 (enExample) |
| WO (2) | WO2015006507A1 (enExample) |
| ZA (1) | ZA201600157B (enExample) |
Families Citing this family (43)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8148330B2 (en) | 2005-12-09 | 2012-04-03 | The Board Of Trustees Of The Leland Stanford Junior University | Modulation of synaptic maintenance |
| US9480658B2 (en) | 2005-12-09 | 2016-11-01 | The Board Of Trustees Of The Leland Stanford Junior University | Modulation of synaptic maintenance |
| EP2912065A4 (en) | 2012-10-25 | 2016-10-19 | True North Therapeutics Inc | ANTI COMPLEMENT C1S ANTIBODIES AND USES THEREOF |
| RS63212B1 (sr) | 2012-11-02 | 2022-06-30 | Bioverativ Usa Inc | Antikomplementna c1s antitela i njihove primene |
| EP2996722A4 (en) * | 2013-05-15 | 2017-01-11 | Annexon, Inc. | Methods of treatment for guillain-barre syndrome |
| KR102321320B1 (ko) | 2013-07-09 | 2021-11-03 | 애넥슨, 인코포레이티드 | 항-보체 인자 ｃ１ｑ 항체 및 이의 용도 |
| US10316081B2 (en) * | 2014-11-05 | 2019-06-11 | Annexon, Inc. | Humanized anti-complement factor C1Q antibodies |
| BR112017021289A2 (en) | 2015-04-06 | 2018-06-26 | Bioverativ Usa Inc. | humanized anti-c1s antibodies and methods of use |
| LT3280441T (lt) | 2015-04-07 | 2021-11-25 | Alector Llc | Anti-sortilino antikūnai ir jų naudojimo būdai |
| BR112018010360A2 (en) * | 2015-11-24 | 2018-12-04 | Annexon, Inc. | anti-c1q complement factor fab fragments and uses thereof |
| US20190161535A1 (en) * | 2016-05-09 | 2019-05-30 | Annexon, Inc. | Compositions and methods for treating spinal muscular atrophy |
| WO2018017711A1 (en) * | 2016-07-19 | 2018-01-25 | Annexon, Inc. | Compositions and methods for treating frontotemporal dementia |
| EP3515932B1 (en) | 2016-09-19 | 2023-11-22 | F. Hoffmann-La Roche AG | Complement factor based affinity chromatography |
| EP3525583B8 (en) | 2016-10-12 | 2025-09-10 | Bioverativ USA Inc. | Anti-c1s antibodies and methods of use thereof |
| CN106699883B (zh) * | 2016-12-19 | 2020-08-07 | 中国兽医药品监察所 | 豚鼠补体C1q-B单克隆抗体60G4的制备与应用 |
| CN106822863A (zh) * | 2017-01-04 | 2017-06-13 | 国家纳米科学中心 | 多肽‑抗体免疫偶联物及其制备方法 |
| CN109843927B (zh) * | 2017-03-06 | 2022-06-21 | 江苏恒瑞医药股份有限公司 | 抗b7-h3抗体、其抗原结合片段及其医药用途 |
| CN111386039B (zh) * | 2017-09-29 | 2023-02-28 | 瑞泽恩制药公司 | 经基因修饰的啮齿动物基因组 |
| EP4640703A2 (en) | 2017-11-14 | 2025-10-29 | Chugai Seiyaku Kabushiki Kaisha | Anti-c1s antibodies and methods of use |
| WO2019137922A1 (en) * | 2018-01-09 | 2019-07-18 | Leibniz-Institut Für Naturstoff-Forschung Und Infektionsbiologie | Modulators of c1q, in particular of the interaction of apoe with c1q, and uses of the modulators in the therapy of neuronal diseases and inflammation |
| EP4257602A3 (en) * | 2018-06-11 | 2023-12-27 | Aarhus Universitet | Single domain antibodies for complement regulation |
| PE20210186A1 (es) | 2018-07-13 | 2021-02-02 | Alector Llc | Anticuerpos anti-sortilina y metodos para su uso |
| US12422440B2 (en) | 2018-10-05 | 2025-09-23 | Seattle Children's Hospital | Newborn screening for primary immunodeficiencies, cystinosis, and Wilson disease |
| JP7499760B2 (ja) * | 2018-11-02 | 2024-06-14 | アネクソン，インコーポレーテッド | 脳損傷を治療するための組成物及び方法 |
| BR112021021689A2 (pt) | 2019-05-15 | 2022-03-22 | Chugai Pharmaceutical Co Ltd | Molécula de ligação a antígeno, composição farmacêutica, e método |
| BR112022006014A2 (pt) * | 2019-10-16 | 2022-07-12 | Chugai Pharmaceutical Co Ltd | Anticorpo, composição farmacêutica e método |
| WO2021076991A1 (en) * | 2019-10-17 | 2021-04-22 | Annexon, Inc. | Compositions and methods for treating blood disorders |
| US11940448B2 (en) | 2020-03-31 | 2024-03-26 | Seattle Children's Hospital | Proteomic screening for lysosomal storage diseases |
| CA3177879A1 (en) * | 2020-05-05 | 2021-12-02 | Jeanne T. PAZ | Compositions and methods for treating epilepsy |
| WO2021226513A1 (en) | 2020-05-08 | 2021-11-11 | President And Fellows Of Harvard College | Methods for treating inflammatory and autoimmune disorders |
| WO2021250323A1 (en) * | 2020-06-09 | 2021-12-16 | Helsingin Yliopisto | Anti-cox-2 autoantibody as a diagnostic marker, and methods, kits and uses related thereto |
| KR20230041758A (ko) * | 2020-07-20 | 2023-03-24 | 애넥슨, 인코포레이티드 | 보체 인자의 저해제 및 이의 용도 |
| AU2021361067A1 (en) * | 2020-10-16 | 2023-06-01 | Annexon, Inc. | Compositions and methods for treating blood disorders |
| CA3200976A1 (en) * | 2020-12-04 | 2022-06-09 | Anita GROVER | Compositions and methods for treating ocular diseases |
| GB202113673D0 (en) * | 2021-09-24 | 2021-11-10 | Reflection Therapeutics Ltd | Targeted cell therapies |
| JP2024539141A (ja) * | 2021-10-21 | 2024-10-28 | アネクソン，インコーポレーテッド | 筋ジストロフィーを治療するための組成物及び方法 |
| US12486322B2 (en) | 2021-12-13 | 2025-12-02 | Annexon, Inc. | Anti-complement factor C1q antibodies with single binding arms and uses thereof |
| EP4453571A1 (en) * | 2021-12-29 | 2024-10-30 | Curateq Biologics Private Limited | C1q binding assay |
| WO2023130001A1 (en) * | 2021-12-30 | 2023-07-06 | Annexon, Inc. | Compositions and methods for treating huntington's disease |
| EP4598575A1 (en) * | 2022-10-07 | 2025-08-13 | Annexon, Inc. | Formulations for anti-c1q antibodies |
| WO2024154122A1 (en) | 2023-01-18 | 2024-07-25 | Gilboa Therapeutics LTD | Immune cells expressing a complement receptor and uses thereof |
| CN119326377B (zh) * | 2024-10-15 | 2025-07-22 | 复旦大学 | 一种基于影像的认知水平评估方法 |
| CN120685919A (zh) * | 2025-08-22 | 2025-09-23 | 中国科学院长春应用化学研究所 | 一种C1q补体蛋白在制备检测Aβ42蛋白的元件中的应用、一种检测Aβ42蛋白的芯片及其应用 |
Family Cites Families (101)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4657760A (en) | 1979-03-20 | 1987-04-14 | Ortho Pharmaceutical Corporation | Methods and compositions using monoclonal antibody to human T cells |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US4595654A (en) | 1983-11-07 | 1986-06-17 | Immunomedics Inc. | Method for detecting immune complexes in serum |
| US5206344A (en) | 1985-06-26 | 1993-04-27 | Cetus Oncology Corporation | Interleukin-2 muteins and polymer conjugation thereof |
| US4676980A (en) | 1985-09-23 | 1987-06-30 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Target specific cross-linked heteroantibodies |
| GB8601597D0 (en) | 1986-01-23 | 1986-02-26 | Wilson R H | Nucleotide sequences |
| US6548640B1 (en) | 1986-03-27 | 2003-04-15 | Btg International Limited | Altered antibodies |
| US5567610A (en) | 1986-09-04 | 1996-10-22 | Bioinvent International Ab | Method of producing human monoclonal antibodies and kit therefor |
| DE3850542T2 (de) | 1987-09-23 | 1994-11-24 | Bristol Myers Squibb Co | Antikörper-Heterokonjugate zur Töting von HIV-infizierten Zellen. |
| GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
| US5175384A (en) | 1988-12-05 | 1992-12-29 | Genpharm International | Transgenic mice depleted in mature t-cells and methods for making transgenic mice |
| DE3920358A1 (de) | 1989-06-22 | 1991-01-17 | Behringwerke Ag | Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung |
| ATE144793T1 (de) | 1989-06-29 | 1996-11-15 | Medarex Inc | Bispezifische reagenzien für die aids-therapie |
| US5225212A (en) | 1989-10-20 | 1993-07-06 | Liposome Technology, Inc. | Microreservoir liposome composition and method |
| US5959177A (en) | 1989-10-27 | 1999-09-28 | The Scripps Research Institute | Transgenic plants expressing assembled secretory antibodies |
| US6075181A (en) | 1990-01-12 | 2000-06-13 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| DE69133566T2 (de) | 1990-01-12 | 2007-12-06 | Amgen Fremont Inc. | Bildung von xenogenen Antikörpern |
| US6150584A (en) | 1990-01-12 | 2000-11-21 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| US5229275A (en) | 1990-04-26 | 1993-07-20 | Akzo N.V. | In-vitro method for producing antigen-specific human monoclonal antibodies |
| JPH06500011A (ja) | 1990-06-29 | 1994-01-06 | ラージ スケール バイオロジー コーポレイション | 形質転換された微生物によるメラニンの製造 |
| US5633425A (en) | 1990-08-29 | 1997-05-27 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| KR100272077B1 (ko) | 1990-08-29 | 2000-11-15 | 젠팜인터내셔날,인코포레이티드 | 이종 항체를 생산할 수 있는 전이유전자를 가진 인간이외의 동물 |
| US5625126A (en) | 1990-08-29 | 1997-04-29 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
| US5661016A (en) | 1990-08-29 | 1997-08-26 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
| US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
| US5571894A (en) | 1991-02-05 | 1996-11-05 | Ciba-Geigy Corporation | Recombinant antibodies specific for a growth factor receptor |
| WO1992020373A1 (en) | 1991-05-14 | 1992-11-26 | Repligen Corporation | Heteroconjugate antibodies for treatment of hiv infection |
| WO1993006217A1 (en) | 1991-09-19 | 1993-04-01 | Genentech, Inc. | EXPRESSION IN E. COLI OF ANTIBODY FRAGMENTS HAVING AT LEAST A CYSTEINE PRESENT AS A FREE THIOL, USE FOR THE PRODUCTION OF BIFUNCTIONAL F(ab')2 ANTIBODIES |
| US5565332A (en) | 1991-09-23 | 1996-10-15 | Medical Research Council | Production of chimeric antibodies - a combinatorial approach |
| FI941572L (fi) | 1991-10-07 | 1994-05-27 | Oncologix Inc | Anti-erbB-2-monoklonaalisten vasta-aineiden yhdistelmä ja käyttömenetelmä |
| WO1993008829A1 (en) | 1991-11-04 | 1993-05-13 | The Regents Of The University Of California | Compositions that mediate killing of hiv-infected cells |
| AU3178993A (en) | 1991-11-25 | 1993-06-28 | Enzon, Inc. | Multivalent antigen-binding proteins |
| ATE419355T1 (de) | 1992-02-06 | 2009-01-15 | Novartis Vaccines & Diagnostic | Marker für krebs und biosynthetisches bindeprotein dafür |
| US5573905A (en) | 1992-03-30 | 1996-11-12 | The Scripps Research Institute | Encoded combinatorial chemical libraries |
| ATE149570T1 (de) | 1992-08-17 | 1997-03-15 | Genentech Inc | Bispezifische immunoadhesine |
| US5789199A (en) | 1994-11-03 | 1998-08-04 | Genentech, Inc. | Process for bacterial production of polypeptides |
| US5840523A (en) | 1995-03-01 | 1998-11-24 | Genetech, Inc. | Methods and compositions for secretion of heterologous polypeptides |
| US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
| US5641870A (en) | 1995-04-20 | 1997-06-24 | Genentech, Inc. | Low pH hydrophobic interaction chromatography for antibody purification |
| US5869046A (en) | 1995-04-14 | 1999-02-09 | Genentech, Inc. | Altered polypeptides with increased half-life |
| US5739277A (en) | 1995-04-14 | 1998-04-14 | Genentech Inc. | Altered polypeptides with increased half-life |
| JP4312259B2 (ja) | 1995-04-27 | 2009-08-12 | アムジェン フレモント インク． | 免疫したゼノマウス（ＸｅｎｏＭｏｕｓｅ）に由来するヒト抗体 |
| EP0823941A4 (en) | 1995-04-28 | 2001-09-19 | Abgenix Inc | HUMAN ANTIBODIES DERIVED FROM IMMUNIZED XENO MOUSES |
| US6717031B2 (en) | 1995-06-07 | 2004-04-06 | Kate Dora Games | Method for selecting a transgenic mouse model of alzheimer's disease |
| US20020058311A1 (en) | 1995-06-13 | 2002-05-16 | Browne Michael Jospeh | Chimeric leptin fused to immunoglobulin domain and use |
| DE19544393A1 (de) | 1995-11-15 | 1997-05-22 | Hoechst Schering Agrevo Gmbh | Synergistische herbizide Mischungen |
| US6037454A (en) | 1996-11-27 | 2000-03-14 | Genentech, Inc. | Humanized anti-CD11a antibodies |
| KR100532178B1 (ko) * | 1996-11-27 | 2005-12-01 | 제넨테크, 인크. | 인간화 항-ＣＤ11ａ 항체 |
| DE69738539T2 (de) | 1996-12-03 | 2009-03-26 | Amgen Fremont Inc. | Vollkommen humane Antikörper die EGFR binden |
| US20050197285A1 (en) | 1997-03-07 | 2005-09-08 | Rosen Craig A. | Human secreted proteins |
| US6040498A (en) | 1998-08-11 | 2000-03-21 | North Caroline State University | Genetically engineered duckweed |
| KR20010023325A (ko) | 1997-08-26 | 2001-03-26 | 리스 데브라 케이. | 함지방세포-특이적 단백질 상동체 |
| JP4460155B2 (ja) | 1997-12-05 | 2010-05-12 | ザ・スクリプス・リサーチ・インステイチユート | マウス抗体のヒト化 |
| GB9809951D0 (en) | 1998-05-08 | 1998-07-08 | Univ Cambridge Tech | Binding molecules |
| US20030170781A1 (en) * | 1999-07-01 | 2003-09-11 | Zymogenetics, Inc. | Secreted protein zacrp4 |
| US7125978B1 (en) | 1999-10-04 | 2006-10-24 | Medicago Inc. | Promoter for regulating expression of foreign genes |
| JP2003512821A (ja) | 1999-10-04 | 2003-04-08 | メディカゴ インコーポレイテッド | 外来性遺伝子の転写調節方法 |
| WO2002005634A2 (en) | 2000-07-13 | 2002-01-24 | University Of South Florida | Transgenic animal and methods |
| US6872559B2 (en) | 2000-10-26 | 2005-03-29 | Wisconsin Alumni Research Foundation | E. coli O157:H7 C1 esterase inhibitor-binding protein and methods of use |
| AU2002233340B2 (en) | 2001-02-19 | 2008-05-22 | Merck Patent Gmbh | Artificial fusion proteins with reduced immunogenicity |
| CA2478313A1 (en) * | 2001-11-07 | 2003-06-26 | Human Genome Sciences, Inc. | 41 human secreted proteins |
| US20040248156A1 (en) * | 2001-12-03 | 2004-12-09 | Tianhua Hu | Methods and materials relating to novel C1q domain-containing polypeptides and polynucleotides |
| US20050214786A1 (en) | 2002-02-22 | 2005-09-29 | Human Genome Sciences, Inc. | 26 human secreted proteins |
| JP2006504971A (ja) | 2002-11-01 | 2006-02-09 | ザ・リージェンツ・オブ・ザ・ユニバーシティ・オブ・コロラド，ア・ボディー・コーポレイト | マトリックス支援レーザー脱離イオン化−飛行時間型質量分析によるタンパク質アイソフォームの定量的解析 |
| JP4768620B2 (ja) | 2003-05-15 | 2011-09-07 | ジェネンテック， インコーポレイテッド | 敗血症の予防及び治療のための方法及び組成物 |
| WO2005002513A2 (en) * | 2003-06-16 | 2005-01-13 | The Brigham And Women's Hospital, Inc. | C1q complement inhibitors and methods of use thereof |
| WO2005002512A2 (en) | 2003-06-19 | 2005-01-13 | University Of Rochester | Immunotherapeutic vaccine strategy |
| US8501705B2 (en) * | 2003-09-11 | 2013-08-06 | The Board Of Regents Of The University Of Texas System | Methods and materials for treating autoimmune and/or complement mediated diseases and conditions |
| US7544855B2 (en) | 2004-04-23 | 2009-06-09 | Buck Institute | Transgenic mouse whose genome comprises an APP having a mutation at amino acid 664 |
| US20080008719A1 (en) | 2004-07-10 | 2008-01-10 | Bowdish Katherine S | Methods and compositions for the treatment of prostate cancer |
| US8420783B2 (en) | 2004-12-08 | 2013-04-16 | Immunomedics, Inc. | Method and compositions for immunotherapy of inflammatory and immune-dysregulatory diseases |
| KR20070107687A (ko) | 2004-12-31 | 2007-11-07 | 제넨테크, 인크. | Ｂｒ３과 결합하는 폴리펩티드, 및 그의 용도 |
| AU2005227420B2 (en) * | 2005-10-14 | 2013-05-09 | Alltech, Inc. | Method and compositions for altering cell function |
| US8148330B2 (en) | 2005-12-09 | 2012-04-03 | The Board Of Trustees Of The Leland Stanford Junior University | Modulation of synaptic maintenance |
| US9480658B2 (en) | 2005-12-09 | 2016-11-01 | The Board Of Trustees Of The Leland Stanford Junior University | Modulation of synaptic maintenance |
| BRPI0709050B1 (pt) * | 2006-03-23 | 2018-12-26 | Bioarctic Neuroscience Ab | anticorpo ou fragmento do mesmo, composição, métodos para detectar protofibrilas ab in vitro, e, uso do anticorpo |
| US7919079B2 (en) | 2006-03-31 | 2011-04-05 | Biosante Pharmaceuticals, Inc. | Cancer immunotherapy compositions and methods of use |
| EP2380907B1 (en) | 2006-09-05 | 2016-11-30 | Alexion Pharmaceuticals, Inc. | Methods and compositions for the treatment of antibody mediated neuropathies |
| CN101657097A (zh) | 2007-03-01 | 2010-02-24 | 先进视觉疗法公司 | 以炎症为特征的疾病的治疗 |
| US8877688B2 (en) | 2007-09-14 | 2014-11-04 | Adimab, Llc | Rationally designed, synthetic antibody libraries and uses therefor |
| CA2697193C (en) | 2007-09-14 | 2017-06-06 | Adimab, Inc. | Rationally designed, synthetic antibody libraries and uses therefor |
| MX2010006422A (es) | 2007-12-11 | 2010-06-25 | Glaxo Group Ltd | Proteinas de union a antigenos. |
| CN105866426B (zh) | 2008-12-01 | 2018-11-23 | 小利兰·斯坦福大学托管委员会 | 用于检测补体结合性抗体的方法和组合物 |
| EP2426916A4 (en) | 2009-04-28 | 2017-09-06 | Panasonic Corporation | Receiver |
| WO2012009568A2 (en) | 2010-07-16 | 2012-01-19 | Adimab, Llc | Antibody libraries |
| WO2012067267A1 (en) | 2010-11-18 | 2012-05-24 | Takahiro Ochi | TESTING METHOD USING ANTI-C1q MONOCLONAL ANTIBODY |
| PH12013502421A1 (en) | 2011-05-27 | 2014-01-06 | Glaxo Group Ltd | Bcma (cd269/tnfrsf17) -binding proteins |
| US9127061B2 (en) | 2011-06-24 | 2015-09-08 | Perseus Proteomics Inc. | Anti-human P-cadherin (CDH3) recombinant antibody |
| PL2794905T3 (pl) | 2011-12-20 | 2020-11-02 | Medimmune, Llc | Zmodyfikowane polipeptydy dla rusztowań przeciwciał dwuswoistych |
| CN118924900A (zh) | 2012-06-18 | 2024-11-12 | 奥默罗斯公司 | 抑制masp-1和/或masp-2和/或masp-3的组合物和方法 |
| EP2912065A4 (en) * | 2012-10-25 | 2016-10-19 | True North Therapeutics Inc | ANTI COMPLEMENT C1S ANTIBODIES AND USES THEREOF |
| RS63212B1 (sr) | 2012-11-02 | 2022-06-30 | Bioverativ Usa Inc | Antikomplementna c1s antitela i njihove primene |
| WO2014161570A1 (en) | 2013-04-03 | 2014-10-09 | Roche Glycart Ag | Antibodies against human il17 and uses thereof |
| US20160053023A1 (en) | 2013-04-09 | 2016-02-25 | Annexon, Inc. | Methods of treatment for neuromyelitis optica |
| EP2996722A4 (en) | 2013-05-15 | 2017-01-11 | Annexon, Inc. | Methods of treatment for guillain-barre syndrome |
| KR102321320B1 (ko) | 2013-07-09 | 2021-11-03 | 애넥슨, 인코포레이티드 | 항-보체 인자 ｃ１ｑ 항체 및 이의 용도 |
| US10316081B2 (en) | 2014-11-05 | 2019-06-11 | Annexon, Inc. | Humanized anti-complement factor C1Q antibodies |
| BR112018010360A2 (en) | 2015-11-24 | 2018-12-04 | Annexon, Inc. | anti-c1q complement factor fab fragments and uses thereof |
| US20190161535A1 (en) | 2016-05-09 | 2019-05-30 | Annexon, Inc. | Compositions and methods for treating spinal muscular atrophy |
| WO2018017711A1 (en) | 2016-07-19 | 2018-01-25 | Annexon, Inc. | Compositions and methods for treating frontotemporal dementia |
| CA3200976A1 (en) | 2020-12-04 | 2022-06-09 | Anita GROVER | Compositions and methods for treating ocular diseases |
-
2014
- 2014-07-09 KR KR1020167002968A patent/KR102321320B1/ko active Active
- 2014-07-09 DK DK14822371.2T patent/DK3019240T3/da active
- 2014-07-09 EP EP14822330.8A patent/EP3019523A4/en not_active Withdrawn
- 2014-07-09 PT PT148223712T patent/PT3019240T/pt unknown
- 2014-07-09 EP EP23174927.6A patent/EP4252769A3/en not_active Withdrawn
- 2014-07-09 MX MX2015017341A patent/MX375500B/es active IP Right Grant
- 2014-07-09 AU AU2014287221A patent/AU2014287221C1/en active Active
- 2014-07-09 BR BR112016000106-0A patent/BR112016000106B1/pt active IP Right Grant
- 2014-07-09 CA CA2916521A patent/CA2916521C/en active Active
- 2014-07-09 SG SG11201510316UA patent/SG11201510316UA/en unknown
- 2014-07-09 SI SI201432076T patent/SI3019240T1/sl unknown
- 2014-07-09 FI FIEP14822371.2T patent/FI3019240T3/fi active
- 2014-07-09 ES ES14822371T patent/ES2978917T3/es active Active
- 2014-07-09 MY MYPI2015003029A patent/MY175896A/en unknown
- 2014-07-09 JP JP2016525467A patent/JP6462680B2/ja active Active
- 2014-07-09 EA EA201690182A patent/EA037325B1/ru unknown
- 2014-07-09 HU HUE14822371A patent/HUE066722T2/hu unknown
- 2014-07-09 EP EP14822371.2A patent/EP3019240B1/en active Active
- 2014-07-09 WO PCT/US2014/046045 patent/WO2015006507A1/en not_active Ceased
- 2014-07-09 SG SG10202008809RA patent/SG10202008809RA/en unknown
- 2014-07-09 PL PL14822371.2T patent/PL3019240T3/pl unknown
- 2014-07-09 SG SG10201710758PA patent/SG10201710758PA/en unknown
- 2014-07-09 WO PCT/US2014/046042 patent/WO2015006504A1/en not_active Ceased
- 2014-07-09 NZ NZ715455A patent/NZ715455A/en unknown
- 2014-07-09 CN CN201480049508.9A patent/CN105682740B/zh active Active
-
2015
- 2015-12-15 MX MX2020010141A patent/MX2020010141A/es unknown
-
2016
- 2016-01-05 US US14/988,387 patent/US20160159890A1/en not_active Abandoned
- 2016-01-06 US US14/989,038 patent/US9708394B2/en active Active
- 2016-01-07 IL IL243506A patent/IL243506B/en unknown
- 2016-01-08 ZA ZA2016/00157A patent/ZA201600157B/en unknown
-
2017
- 2017-04-19 US US15/491,574 patent/US10227398B2/en active Active
-
2018
- 2018-12-27 JP JP2018243892A patent/JP6653009B2/ja active Active
-
2019
- 2019-01-04 US US16/239,685 patent/US10590190B2/en active Active
-
2020
- 2020-02-06 US US16/784,020 patent/US10927167B2/en active Active
-
2021
- 2021-02-10 US US17/172,807 patent/US11649279B2/en active Active
-
2023
- 2023-02-16 US US18/110,574 patent/US20240083987A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016526393A5 (enExample) | ||
| JP2018501813A5 (enExample) | ||
| CN110291109B (zh) | 人程序性死亡受体pd-1的单克隆抗体及其片段 | |
| TWI673287B (zh) | 抗b7-h3抗體、其抗原結合片段及其醫藥用途 | |
| US11472882B2 (en) | Anti-B7-H4 antibody, antigen-binding fragment thereof and pharmaceutical use thereof | |
| CN107001459B (zh) | 用于治疗炎症和自身免疫紊乱的抗age抗体 | |
| JP2019501132A5 (enExample) | ||
| JP7476997B2 (ja) | 二重特異性抗体 | |
| JP2019518459A (ja) | Ｌａｇ−３抗体、その抗原結合フラグメント、およびそれらの医薬的用途 | |
| TW201902924A (zh) | 抗－N3pGlu類澱粉β肽抗體及其用途 | |
| JP2010504755A5 (enExample) | ||
| CN103946238A (zh) | 抗ox40抗体及使用其的方法 | |
| KR20160062167A (ko) | 죽상경화증의 치료를 위한 세마포린-4d 결합 분자의 용도 | |
| US20180148499A1 (en) | Antibody Therapy for Amyloid Beta Disease | |
| WO2018219327A1 (zh) | 抗cd40抗体、其抗原结合片段及其医药用途 | |
| JP2021506922A (ja) | Ｌａｇ−３抗体医薬組成物およびその使用 | |
| JP2020536495A (ja) | 抗ｌａｇ−３抗体及びその使用 | |
| AU2017312049A1 (en) | Methods of treating Crohn's Disease with an anti-NKG2D antibody | |
| TW202342101A (zh) | 抗EphA4抗體 | |
| WO2019076277A1 (zh) | 抗pd-1抗体和抗lag-3抗体联合在制备治疗肿瘤的药物中的用途 | |
| WO2022228183A1 (zh) | 抗siglec15抗体及其制备方法和用途 | |
| CN112513088A (zh) | 抗ox40抗体、其抗原结合片段及其医药用途 | |
| CA3156983A1 (en) | Antibodies against the poliovirus receptor (pvr) and uses thereof | |
| WO2022237647A1 (zh) | 针对dll3的结合分子及其应用 | |
| CN112243443A (zh) | 抗trop-2抗体、其抗原结合片段及其医药用途 |